GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
Enrolling By Invitation
The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI \> 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who continue with the current standard of care for patients who have previously undergone Ga... Read More
Gender:
ALL
Ages:
Between 30 years and 65 years
Trial Updated:
03/07/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Severe Obesity, Obesity, BMI Greater Than 30
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity
Active Not Recruiting
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Lynn Institute of Chattanooga, Chattanooga, Tennessee
Conditions: Obesity
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: WR-Clinsearch, LLC, Chattanooga, Tennessee
Conditions: Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: WR-Clinsearch, LLC, Chattanooga, Tennessee
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Completed
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Holston Medical Group, Bristol, Tennessee +1 locations
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Holston Medical Group, Bristol, Tennessee
Conditions: Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Holston Medical Group Clinical Research, Kingsport, Tennessee +1 locations
Conditions: Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Completed
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2021
Locations: New Phase Research & Development, Knoxville, Tennessee
Conditions: Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
Completed
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/31/2019
Locations: New Phase Research & Development, Knoxville, Tennessee +1 locations
Conditions: Type 2 Diabetes Mellitus